CN103933487A - 一种治疗抑郁症的复方中药 - Google Patents
一种治疗抑郁症的复方中药 Download PDFInfo
- Publication number
- CN103933487A CN103933487A CN201410194263.0A CN201410194263A CN103933487A CN 103933487 A CN103933487 A CN 103933487A CN 201410194263 A CN201410194263 A CN 201410194263A CN 103933487 A CN103933487 A CN 103933487A
- Authority
- CN
- China
- Prior art keywords
- depression
- traditional chinese
- parts
- compound traditional
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 150000001875 compounds Chemical class 0.000 title claims abstract description 28
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 6
- 241001522129 Pinellia Species 0.000 claims abstract description 6
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 5
- 235000008434 ginseng Nutrition 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims abstract description 3
- 235000017491 Bambusa tulda Nutrition 0.000 claims abstract description 3
- 241000675108 Citrus tangerina Species 0.000 claims abstract description 3
- 244000082204 Phyllostachys viridis Species 0.000 claims abstract description 3
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims abstract description 3
- 244000197580 Poria cocos Species 0.000 claims abstract description 3
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 3
- 239000011425 bamboo Substances 0.000 claims abstract description 3
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract 2
- 241000202726 Bupleurum Species 0.000 claims description 5
- 240000004670 Glycyrrhiza echinata Species 0.000 claims description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 5
- 229940010454 licorice Drugs 0.000 claims description 5
- 240000003791 Citrus myrtifolia Species 0.000 claims description 4
- 235000000228 Citrus myrtifolia Nutrition 0.000 claims description 4
- 235000016646 Citrus taiwanica Nutrition 0.000 claims description 4
- 208000020401 Depressive disease Diseases 0.000 claims description 4
- 235000014375 Curcuma Nutrition 0.000 claims description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 3
- 244000164439 Curcuma angustifolia Species 0.000 claims 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 1
- 229910052707 ruthenium Inorganic materials 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 13
- 239000000203 mixture Substances 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 8
- 210000000952 spleen Anatomy 0.000 abstract description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 7
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 abstract description 7
- 229960000258 corticotropin Drugs 0.000 abstract description 7
- 208000026435 phlegm Diseases 0.000 abstract description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract description 6
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 6
- 230000003542 behavioural effect Effects 0.000 abstract description 6
- 229910052802 copper Inorganic materials 0.000 abstract description 6
- 239000010949 copper Substances 0.000 abstract description 6
- 229910052725 zinc Inorganic materials 0.000 abstract description 6
- 239000011701 zinc Substances 0.000 abstract description 6
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 5
- 230000001684 chronic effect Effects 0.000 abstract description 4
- 230000007812 deficiency Effects 0.000 abstract description 3
- 210000003016 hypothalamus Anatomy 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 2
- 230000000384 rearing effect Effects 0.000 abstract description 2
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 101800000414 Corticotropin Proteins 0.000 abstract 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 abstract 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- JYGXADMDTFJGBT-MKIDGPAKSA-N 11alpha-Hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-MKIDGPAKSA-N 0.000 abstract 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 abstract 1
- 244000183685 Citrus aurantium Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 241001559542 Hippocampus hippocampus Species 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 244000163122 Curcuma domestica Species 0.000 description 4
- 230000000971 hippocampal effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 240000004371 Panax ginseng Species 0.000 description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 3
- 210000004727 amygdala Anatomy 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000010227 chenpi Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000004518 granules dosage form Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010049976 Impatience Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000001720 action spectrum Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004938 stress stimulation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
一种治疗抑郁症的复方中药,涉及复方中药。按质量比的原料组成为:柴胡0.5~2、郁金0.5~2、人参0.5~2、半夏0.3~1、茯苓1~3、陈皮0.5~1.5、枳实0.5~1、竹茹0.3~1、甘草0~1。解郁化痰,健脾养心,用于轻、中度抑郁症属于气郁痰阻、心脾两虚者。药效学研究表明:药物组合物可显著拮抗慢性轻度不可预见性应激抑郁症大鼠,增加模型大鼠水平得分与垂直得分,改善行为学状态,其作用机理与改善下丘脑NE、DA、5-HT含量、血清ACTH、COR浓度以及海马cAMP含量、血清铜、锌含量密切相关。
Description
技术领域
本发明涉及复方中药,尤其是涉及一种治疗抑郁症的复方中药。
背景技术
抑郁症是一种常见的心境障碍,可由各种原因引起,以显著而持久的心境低落为主要临床特征,严重者可出现自杀念头和行为。据世界卫生组织统计,全球抑郁症的发病率为11%,发病人数多达1.2亿,已成为世界第4大疾患,预计到2020年,抑郁症可能成为仅次于冠心病的第二大疾病。近年来,由于工作节奏加快、生活压力增大、各种应激因素增加,我国抑郁症的发病率不断升高,已达12.5%,并呈低龄化趋势。然而,由于本病的病因与发病机制错综复杂,尚未完全阐明,药物治疗或仅针对某种机制,其作用谱较窄,或需长期服用,甚或出现肝肾毒性等不良反应,临床应用受到限制。因此,加强抑郁症治疗方案的研究,对防治本病具有重大的科学和社会意义。
中医学虽无抑郁症病名记载,但根据其症状,可将其归属于中医“郁证”、“百合病”、“脏躁”等范畴。因其初起多以气郁、痰阻等邪实为主,病久耗伤气血,损及心脾而成虚实夹杂之证。业已证实,中药复方多途径、多环节的抗抑郁症综合效应,是其中医药整体观念的优势体现,已经成为抑郁症防治研究的一种重要策略。中国专利CN102370727A公开一种治疗抑郁症的复方中药制剂,包括下述重量配比的中药原料:柴胡8~12、白芍8~12、茯苓10~14、当归8~12、半夏10~14、厚朴8~12、石菖蒲8~12、郁金8~12、龙骨13~17、牡蛎13~17、甘草5~7;其制备方法是将上述11味药材洗净,按比例混合,加药材总重量的6~8倍的水或体积比为70%的乙醇煎煮3次,每次50分钟,合并3次煎煮液,过滤,并浓缩,得到60℃时比重为1.17的流浸膏,采用常规制备工艺,可制成任何一种药剂学上所说的剂型,如片剂、胶囊剂、颗粒剂、口服液、丸剂、糖浆剂。
发明内容
本发明的目的是提供一种治疗抑郁症的复方中药。
本发明按质量比的原料组成为:柴胡0.5~2、郁金0.5~2、人参0.5~2、半夏0.3~1、茯苓1~3、陈皮0.5~1.5、枳实0.5~1、竹茹0.3~1、甘草0~1。
本发明所述治疗抑郁症的复方中药的制备方法可以采用制药领域的常规方法,使用常规的药用辅料进行。例如采用一般方法将提取物与至少一种药剂学上常用的载体或辅料混合,然后制成各种口服剂型。所述载体可选自赋形剂、填料、稀释剂、润滑剂、湿润剂、崩解剂、表面活性剂、防腐剂、甜味剂、芳香剂等中的至少一种。具体地,所述载体例如淀粉、糊精、乳糖、微晶纤维素、羟丙甲基纤维素、聚乙二醇、硬脂酸镁、微粉硅胶、葡萄糖、甘露醇、木糖醇、甘氨酸等。
根据需要,本发明所述治疗抑郁症的复方中药可制成适于口服用药的制剂,所述制剂可选自片剂、胶囊剂、软胶囊剂、颗粒剂、滴丸、分散片、口腔崩解片、丸剂、口服液等中的一种。
本发明所述治疗抑郁症的复方中药可煎煮后服用,也可以用水或乙醇提取后服用。
本发明所述治疗抑郁症的复方中药的使用剂量,若以颗粒剂型为例,患者每日服药量为10g,制备时可每袋以5g装,每次服用1袋,1天服用2次,连续服用1个月为1疗程。
本发明处方药味合用,具有解郁化痰,健脾养心的功能。对该方提取的组合物的药理研究表明,该组合物对慢性轻度不可预见性应激抑郁症模型大鼠具有特异性抗抑制作用,显著增加模型大鼠水平得分与垂直得分等行为学评分。
本发明公开了一种用于治疗抑郁症的复方中药。它以柴胡、郁金、人参、半夏、茯苓、陈皮、枳实、竹茹、甘草为原料,经过0~75%乙醇提取分离,制成一定的剂型。上述九药合用,解郁化痰,健脾养心,用于轻、中度抑郁症属于气郁痰阻、心脾两虚者。药效学研究表明:药物组合物可显著拮抗慢性轻度不可预见性应激抑郁症大鼠,增加模型大鼠水平得分与垂直得分,改善行为学状态,其作用机理与改善下丘脑NE、DA、5-HT含量、血清ACTH、COR浓度以及海马cAMP含量、血清铜、锌含量密切相关。该组合物可以制成医学上可以接受的口服制剂,如片剂、胶囊剂(软胶囊或硬胶囊)、颗粒剂等剂型,从药效学研究证明本发明具有解郁化痰,健脾养心之功能,是治疗抑郁症的有效复方。
具体实施方式
为了对本发明进行更进一步的详细描述,给出具体实施例,但仅作为阐明本发明,而不是为了限制本发明的范围。
实施例1本发明药物组合物的颗粒剂剂型
采用常规制备颗粒剂方法,取柴胡1份(所述份可按100g计算,以下相同)、郁金1份、人参1份、半夏1份、茯苓3份、陈皮1份、枳实0.5份、竹茹1份、甘草0.5份,加水量分别为10倍、8倍,第一次提取2h,第二次提取1.5h,过滤,合并滤液,浓缩、干燥、粉碎后加辅料适量,混匀,制粒,过筛,干燥,制得颗粒剂型的药物组合物制剂。
实施例2本发明组合物的药效试验及机理研究
本试验的目的在于观察本发明组合物对大鼠抑郁模型的治疗作用。具体如下:
1材料
1.1实验动物SD雄性大鼠,40只,清洁级,180g左右,由南京医科大学实验动物中心提供,许可证号SCXK(苏)2002-0031。
1.2药物本发明组合物采用颗粒剂,用时以纯净水配制所需浓度。其他试剂药品有马普替林,购于北京诺华制药有限公司生产,用之前以双蒸水配制成1mg/ml混悬液。
1.3模型制备采用慢性轻度不可预见性应激的大鼠抑郁模型。正常对照组每笼饲养6只,正常摄水饮食,不给任何刺激。除正常对照组外的其余大鼠,每只均单笼饲养,并接受21天各种不同的应激刺激,刺激方法,根据Katz方法改进,包括:2次48h禁食,2次24h禁水,2次通宵照明(12h),2次4℃冰水游泳5min,2次45℃烘箱热烘5min,2次夹尾1min,2次高水平振荡(160Hz)10min,2次昼夜颠倒,2次24h潮湿饲养(将200ml水加入铺有一层锯木屑的笼底使锯木屑全部浸湿)及1次闪光刺激(120次/s)15min。每天随机给予一种刺激,使大鼠不能预见刺激的发生,以避免产生适应。
2方法
2.1造模与分组用药将SD雄性大鼠,随机分为正常组、模型组、复方中药组、马普替林组,每组大鼠10只。模型组、复方中药组、马普替林组按照上述模型制备方案随机给予应激刺激21天。药物组按1ml/100g鼠重分别灌服相应的药物,每天1次,正常组、模型组给予相应量的饮用水灌胃。
2.2观察指标
●Open-Field行为评分:在实验的第1天、第22天行Open-Field行为学评分。
●下丘脑NE、DA、5-HT含量检测。
●血清ACTH、COR浓度以及海马cAMP含量检测。
●血清铜、锌含量检测。
3结果
3.1复方中药对大鼠行为学的影响。
抑郁症模型大鼠体质量增长缓慢,水平和垂直活动及糖水消耗量均明显减少(P<0.05,P<0.01)。而复方中药能显著改善大鼠行为学指标,具有显著抗抑郁作用,为后续进行中药复方抗抑郁症的相关研究提供了科学的药效学依据。
3.2复方中药对大鼠血清ACTH、COR和海马cAMP含量的影响
复方中药显著降低血清ACTH、COR浓度、提升海马cAMP含量,参与调节HPA轴功能(表1)。
表1各组大鼠血清ACTH、COR和海马cAMP含量变化
注:ΔP<0.05,ΔΔP<0.01vs正常组;▲P<0.05,▲▲P<0.01vs模型组。
3.3复方中药对大鼠杏仁核NE、5-HT、DA含量的影响
复方中药显著升高杏仁核NE、5-HIAA、5-HT、HVA、DA含量,参与对中枢单胺类神经递质的调节(表2)。
表2各组大鼠杏仁核NE、5-HT、DA含量变化
注:ΔP<0.05,ΔΔP<0.01vs正常组;▲P<0.05,▲▲P<0.01vs模型组。
3.4复方中药对大鼠血清铜、锌含量的影响
复方中药显著提高血清锌含量、降低血清铜含量,参与调节微量元素(表3)。
表3各组大鼠血清铜、锌含量变化
注:ΔP<0.05vs正常组;▲P<0.05,▲▲P<0.01vs模型组
药效学研究结果表明,本发明药物组合物是治疗抑郁症的有效药物。
Claims (1)
1.一种治疗抑郁症的复方中药,其特征在于按质量比的原料组成为:柴胡0.5~2、郁金0.5~2、人参0.5~2、半夏0.3~1、茯苓1~3、陈皮0.5~1.5、枳实0.5~1、竹茹0.3~1、甘草0~1。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410194263.0A CN103933487A (zh) | 2014-05-09 | 2014-05-09 | 一种治疗抑郁症的复方中药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410194263.0A CN103933487A (zh) | 2014-05-09 | 2014-05-09 | 一种治疗抑郁症的复方中药 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103933487A true CN103933487A (zh) | 2014-07-23 |
Family
ID=51181543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410194263.0A Pending CN103933487A (zh) | 2014-05-09 | 2014-05-09 | 一种治疗抑郁症的复方中药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103933487A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104173800A (zh) * | 2014-08-19 | 2014-12-03 | 冯小明 | 一种治疗抑郁症的中药制剂及其制备方法 |
CN104189867A (zh) * | 2014-09-26 | 2014-12-10 | 田胜硕 | 一种治疗精神分裂症后抑郁的中药组合物 |
CN104288677A (zh) * | 2014-09-26 | 2015-01-21 | 广西中医药大学 | 一种治疗抑郁症的瑶药复合物及其制备方法 |
CN112043807A (zh) * | 2020-09-03 | 2020-12-08 | 中国人民解放军63919部队 | 一种抗抑郁中药复方 |
CN115501305A (zh) * | 2022-10-25 | 2022-12-23 | 许二平 | 治疗肝郁脾虚湿盛型抑郁症的中药组合物及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1308959A (zh) * | 2001-01-12 | 2001-08-22 | 王东桥 | 一种治疗神志病(精神病等)的药物-怡神解郁方剂 |
CN101011561A (zh) * | 2006-11-01 | 2007-08-08 | 黄达驹 | 黄连温胆汤现代中药口服制剂及其生产方法 |
CN101530599A (zh) * | 2009-04-20 | 2009-09-16 | 高新华 | 一种治疗精神抑郁的药物组合物 |
-
2014
- 2014-05-09 CN CN201410194263.0A patent/CN103933487A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1308959A (zh) * | 2001-01-12 | 2001-08-22 | 王东桥 | 一种治疗神志病(精神病等)的药物-怡神解郁方剂 |
CN101011561A (zh) * | 2006-11-01 | 2007-08-08 | 黄达驹 | 黄连温胆汤现代中药口服制剂及其生产方法 |
CN101530599A (zh) * | 2009-04-20 | 2009-09-16 | 高新华 | 一种治疗精神抑郁的药物组合物 |
Non-Patent Citations (1)
Title |
---|
陈艳玲等: "柴郁温胆汤及其拆方对慢性应激抑郁大鼠的作用", 《安徽中医学院学报》, vol. 32, no. 2, 30 April 2013 (2013-04-30), pages 64 - 68 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104173800A (zh) * | 2014-08-19 | 2014-12-03 | 冯小明 | 一种治疗抑郁症的中药制剂及其制备方法 |
CN104173800B (zh) * | 2014-08-19 | 2017-09-08 | 冯小明 | 一种治疗抑郁症的中药制剂及其制备方法 |
CN104189867A (zh) * | 2014-09-26 | 2014-12-10 | 田胜硕 | 一种治疗精神分裂症后抑郁的中药组合物 |
CN104288677A (zh) * | 2014-09-26 | 2015-01-21 | 广西中医药大学 | 一种治疗抑郁症的瑶药复合物及其制备方法 |
CN104288677B (zh) * | 2014-09-26 | 2017-11-03 | 广西中医药大学 | 一种治疗抑郁症的瑶药复合物及其制备方法 |
CN112043807A (zh) * | 2020-09-03 | 2020-12-08 | 中国人民解放军63919部队 | 一种抗抑郁中药复方 |
CN115501305A (zh) * | 2022-10-25 | 2022-12-23 | 许二平 | 治疗肝郁脾虚湿盛型抑郁症的中药组合物及其用途 |
CN115501305B (zh) * | 2022-10-25 | 2023-11-21 | 许二平 | 治疗肝郁脾虚湿盛型抑郁症的中药组合物及其用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103933487A (zh) | 一种治疗抑郁症的复方中药 | |
CN104922176A (zh) | 一种野菊花提取物的应用 | |
CN104840527A (zh) | 一种含远志糖酯和人参皂苷的组合物及用途 | |
CN111437338A (zh) | 一种中药组合物在治疗皮肤病中的用途 | |
CN101181285A (zh) | 黄芪甲苷在制备治疗神经退行性疾病药物中的应用 | |
CN105920143A (zh) | 一种贯叶金丝桃和栀子的药物组合物及其抗抑郁的医药用途 | |
CN101810337A (zh) | 三七灵芝黄芪保健食品 | |
CN104013753B (zh) | 用于治疗骨关节炎的中药提取物及其制备方法 | |
CN102389496A (zh) | 一种治疗肝炎的中药组合物及其制备方法 | |
CN101433645B (zh) | 一种抗抑郁与应激性心理障碍的中药制剂及其制备方法 | |
CN101422570B (zh) | 一种提高男性性功能的功能性食品 | |
CN101152196A (zh) | 三七总皂苷及其单体在制备治疗抑郁症药物中的应用 | |
CN103830337B (zh) | 一种治疗慢性酒精中毒性肝病的中药组合物 | |
CN103251757A (zh) | 一种含冰片的复方制剂及其制备方法和应用 | |
CN102274428B (zh) | 一种具有治疗肠易激综合症作用的药物组合物及其制备方法和应用 | |
CN1272018C (zh) | 甘草苷在制备预防和/或治疗抑郁症药物中的应用 | |
CN108295168B (zh) | 一种治疗卒中后抑郁的中药组合物 | |
CN1931286A (zh) | 一种用于治疗肺癌等引起的轻、中度癌性疼痛属气滞血瘀证的中药组合物 | |
CN102631486B (zh) | 一种保健组合物 | |
CN116999533B (zh) | 一种养心生脉颗粒及其制法和在抗抑郁的产品中的应用 | |
CN102631506B (zh) | 提高免疫力、抗疲劳的中药组合物 | |
CN115154538B (zh) | 一种具有降血尿酸作用的中药组合物及其应用 | |
CN103920023A (zh) | 一种治疗高血压的中药 | |
CN103893512B (zh) | 一种治疗痛风性关节炎的中药组合物 | |
CN103598588B (zh) | 一种具有改善睡眠作用的保健食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140723 |
|
RJ01 | Rejection of invention patent application after publication |